A Randomized, Vehicle-controlled, Subject and Investigator-masked, Proof-of-concept Study to Evaluate the Use of Topical Ocular SAF312 in the Treatment of Postoperative Ocular Pain in Patients Undergoing Photorefractive Keratectomy (PRK) Surgery
Phase of Trial: Phase II
Latest Information Update: 13 Oct 2017
At a glance
- Drugs SAF 312 (Primary)
- Indications Ocular pain; Postoperative pain
- Focus Proof of concept; Therapeutic Use
- Sponsors Novartis; Novartis Pharmaceuticals
- 10 Oct 2017 Planned End Date changed from 22 Jan 2018 to 19 Feb 2018.
- 10 Oct 2017 Planned primary completion date changed from 21 Dec 2017 to 18 Jan 2018.
- 23 Jul 2017 Planned End Date changed from 1 Apr 2017 to 22 Jan 2018.